Scarica l'app Stockscreener
37.49
2.68%
0.98
Dopo l'orario di chiusura:
37.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Precedente Chiudi:
$36.51
Aprire:
$36.66
Volume 24 ore:
956.51K
Relative Volume:
0.81
Capitalizzazione di mercato:
$3.93B
Reddito:
$7.70M
Utile/perdita netta:
$-465.32M
Rapporto P/E:
-7.582
EPS:
-4.9446
Flusso di cassa netto:
$-383.68M
1 W Prestazione:
-1.94%
1M Prestazione:
-12.20%
6M Prestazione:
+10.26%
1 anno Prestazione:
+6.99%
Intervallo 1D:
$35.85
$37.71
Intervallo di 1 settimana:
$35.43
$39.28
Portata 52W:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Nome
Crinetics Pharmaceuticals Inc
Settore
Industria
Telefono
858-450-6464
Indirizzo
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
37.49 | 3.93B | 7.70M | -465.32M | -383.68M | -4.9446 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-10 | Iniziato | Goldman | Neutral |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-11 | Iniziato | TD Cowen | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Peer Perform |
| 2025-01-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-01-16 | Iniziato | Morgan Stanley | Overweight |
| 2023-12-21 | Iniziato | Jefferies | Hold |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Iniziato | Oppenheimer | Outperform |
| 2023-04-24 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-23 | Iniziato | Evercore ISI | Outperform |
| 2021-06-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Iniziato | ROTH Capital | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-13 | Iniziato | JP Morgan | Neutral |
| 2018-08-13 | Iniziato | Leerink Partners | Outperform |
| 2018-08-13 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now? - simplywall.st
Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential - Yahoo Finance
Insider Sell: Coelho Vivaldi Sells 5,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) - GuruFocus
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - Sahm
Income Plays: Can Crinetics Pharmaceuticals Inc stock outperform in a bear market2026 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Systematic review on acromegaly therapies receives journal approval, Crinetics Pharmaceuticals announces - Traders Union
(CRNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
WINTON GROUP Ltd Takes Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Levels Update: Is Crinetics Pharmaceuticals Inc a stock for growth or value investorsMarket Activity Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf. - Yahoo Finance
Should value investors consider Crinetics Pharmaceuticals Inc2026 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Will Crinetics Pharmaceuticals Inc. stock attract more institutional investorsInsider Buying & High Win Rate Trade Alerts - Naître et grandir
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Insider Trends: What is the dividend yield of Crinetics Pharmaceuticals IncJuly 2025 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
American Century Companies Inc. Has $47.21 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharma CFO Schilke sells $266k in stock By Investing.com - Investing.com Canada
Crinetics Pharma CFO Schilke sells $266k in stock - Investing.com
Insider Sell: Stephanie Okey Sells 3,000 Shares of Crinetics Pha - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Stephanie Okey Sells 3,000 Shares - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) CFO Tobin Schilke Sells 6,713 Shares - MarketBeat
Crinetics (CRNX) director sells 3,000 shares under 10b5-1 plan - Stock Titan
Crinetics (NASDAQ: CRNX) CFO sells 6,713 shares to cover taxes - Stock Titan
CRNX: Strong launch, advancing pipeline, and EU expansion position for major growth in rare endocrine diseases - TradingView
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Auditor change at Crinetics (NASDAQ: CRNX) names PwC - Stock Titan
Crinetics Pharmaceuticals (CRNX) Stock Analysis: Unpacking a 105% Potential Upside for Growth Investors - DirectorsTalk Interviews
Why Crinetics Pharmaceuticals (CRNX) Is Down 7.1% After Deeper 2025 Loss And New US$207 Million Shelf Registration - Sahm
Does Crinetics Pharmaceuticals, Inc. (CRNX) Have Momentum? - AAII.com
CRNX: Analyst Maintains "Market Outperform" but Lowers Price Tar - GuruFocus
Citizens Jmp Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $96.00 - MarketBeat
[144] Crinetics Pharmaceuticals, Inc. SEC Filing - Stock Titan
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
(CRNX) Risk Channels and Responsive Allocation - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen - MarketBeat
Crinetics Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CRNX) 2026-02-27 - Seeking Alpha
Crinetics Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Vanguard Group Inc. Sells 86,003 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Palsonfi Launch Momentum And ESOP Shelf Registration Altering The Investment Case For Crinetics (CRNX)? - Yahoo Finance
Crinetics Pharmaceuticals (CRNX) TTM Loss Of US$465 Million Tests Bullish Long Term Narratives - Sahm
Crinetics Pharmaceuticals Inc (CRNX) Q4 2025 Earnings Call Highl - GuruFocus
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics Pharmaceuticals (CRNX) Reports Strong Q4 2025 Performa - GuruFocus
Crinetics Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Crinetics Pharmaceuticals Q4 2025 earnings beat forecasts - Investing.com
Crinetics (CRNX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Crinetics Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Crinetics (CRNX) Exceeds Revenue Expectations and Looks to Expan - GuruFocus
Crinetics Pharmaceuticals Inc Azioni (CRNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):